Autor: Andrew Davis

Andrew Davis read Chemistry at Imperial College of Science and Technology and then completed a Ph D in Physical Organic Chemistry with Professor MI Page at the University of Huddersfield. He joined Fisons PLC Pharmaceuticals Division in 1988, which became part of the Swedish pharmaceutical company Astra AB in 1995. Astra merged with Zeneca PLC in 1999 to form Astra Zeneca PLC. Dr Davis has spent the last 23 years in drug discovery, in line management, project and portfolio management and senior science roles. He has recently relocated to Sweden with Astra Zeneca as Senior Principal Scientist and project leader in Chemistry with the Respiratory and Inflammation Innovative Medicines in Gothenburg. Simon Ward has an MA in Natural Sciences and a Ph D in synthetic organic chemistry from Cambridge University. He has a wide ranging experience of drug discovery in both large and small companies (Glaxo Smith Kline, Knoll Pharmaceuticals, Vernalis, Chiroscience) and specialist experience of discovering and developing drugs for central nervous system indications. He has led multidisciplinary project teams and medicinal chemistry groups from target identification, through to early clinical studies, delivering multiple clinical development candidates across indications. Simon is a Fellow of the Royal Society of Chemistry and is currently Professor of Medicinal Chemistry at the University of Sussex, UK and Director of the Translational Drug Discovery Group, which he established within the University of Sussex in 2010.